Patent application number | Description | Published |
20090143375 | Tricyclic Lactam Derivatives, Their Manufacture and Use as Pharmaceutical Agents - Objects of the present invention are the compounds of formula I | 06-04-2009 |
20090264485 | Pyrazole Derivatives, Their Manufacture and Their Use as Pharmaceutical Agents - Objects of the present invention are the compounds of formula I | 10-22-2009 |
20100261672 | PHARMACEUTICAL COMPOSITIONS OF PYRIMIDINE-2,4,6-TRIONES - A trioxopyrimidine-cyclodextrin complex formed of a trioxopyrimidine derivative or a salt thereof and a water-soluble cyclodextrin derivative has improved solubility. | 10-14-2010 |
20100310567 | Antibodies Against Human CCN1 and Uses Thereof - Disclosed herein are methods for the recombinant expression of mammalian cell membrane-bound human CCN1 or a CCN1 domain thereof in mammalian cells, comprising transforming a mammalian host cell with a vector encoding CCN1 or a CCN1 domain thereof C-terminally fused to a mammalian cell transmembrane domain (CCN1 fusion protein), expressing said CCN1 or CCN1 domain fusion protein in said host cell, and recovering said membrane bound CCN1 or said CCN1 domain thereof. Disclosed herein is the use of such membrane bound CCN1 and domain for the generation of corresponding antibodies. Antibodies against human CCN1 are useful for the treatment of diseases. | 12-09-2010 |
20110059093 | USE OF AN ANTI-TAU PS422 ANTIBODY FOR THE TREATMENT OF BRAIN DISEASES - An antibody binding to Tau that is phosphorylated at serine 422 (pS422), which specifically binds to phosphorylated Tau fragment of SEQ ID NO:9 and to Tau pS422, but does not bind to Tau and to phosphorylated MCAK fragment of SEQ ID NO:17. The antibody is useful in the treatment of a Tauopathy. | 03-10-2011 |
20110070246 | Antibodies Against CDCP1 for the Treatment of Cancer - The present invention relates to antibodies against human CDCP1 binding to the same epitope as CUB4 (Deposition No. DSM ACC2551) for the treatment of cancer. | 03-24-2011 |
20110171222 | ANTI-HER3 ANTIBODIES AND USES THEREOF - The present invention relates to antibodies binding to human HER3 (anti-HER3 antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof. | 07-14-2011 |
20110306094 | METHOD FOR OBTAINING IMMUNOGLOBULIN ENCODING NUCLEIC ACID - The current invention is directed to a method for obtaining a nucleic acid encoding an immunoglobulin variable domain from a single cell comprising the following steps:—performing a first polymerase chain reaction with three to six 5′-primer and one 3′-primer, performing with the product of the first polymerase chain reaction a second polymerase chain reaction with thirteen to sixteen 5′-primer and one 3′-primer, whereby the distance of the binding locations of the primer employed in the second polymerase chain reaction is reduced compared to the first polymerase chain reaction. | 12-15-2011 |
20120020988 | Antibodies specifically binding to human TSLPR and methods of use - An antibody specifically binding to human thymic stromal lymphopoietin receptor (TSLPR), characterized in comprising as heavy chain variable domain CDR regions a CDR1 region of SEQ ID NO:2 or 17, a CDR2 region of SEQ ID NO:3 or 10, and CDR3 region of SEQ ID NO:4, and as light chain variable domain CDR regions a CDR1 region of SEQ ID NO:6 or 12, a CDR2 region of SEQ ID NO:7, 13 or 15, and a CDR3 region of SEQ ID NO:8. is useful for the treatment of immunological diseases. | 01-26-2012 |
20120258112 | ANTIBODIES AGAINST HUMAN CCN1 AND USES THEREOF - Disclosed herein are methods for the recombinant expression of mammalian cell membrane-bound human CCN1 or a CCN1 domain thereof in mammalian cells, comprising transforming a mammalian host cell with a vector encoding CCN1 or a CCN1 domain thereof C-terminally fused to a mammalian cell transmembrane domain (CCN1 fusion protein), expressing said CCN1 or CCN1 domain fusion protein in said host cell, and recovering said membrane bound CCN1 or said CCN1 domain thereof. Disclosed herein is the use of such membrane bound CCN1 and domain for the generation of corresponding antibodies. Antibodies against human CCN1 are useful for the treatment of diseases. | 10-11-2012 |
20130310541 | USE OF AN ANTI-TAU PS422 ANTIBODY FOR THE TREATMENT OF BRAIN DISEASES - An antibody binding to Tau that is phosphorylated at serine 422 (pS422), which specifically binds to phosphorylated Tau fragment of SEQ ID NO:9 and to Tau pS422, but does not bind to Tau and to phosphorylated MCAK fragment of SEQ ID NO:17. The antibody is useful in the treatment of a Tauopathy. | 11-21-2013 |
20140377272 | ANTI-HER3 ANTIBODIES AND USES THEREOF - The present invention relates to antibodies binding to human HER3 (anti-HER3 antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof. | 12-25-2014 |
20140377273 | ANTI-HER3 ANTIBODIES AND USES THEREOF - The present invention relates to antibodies binding to human HER3 (anti-HER3 antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof. | 12-25-2014 |
20150024434 | METHOD FOR OBTAINING FAB FRAGMENTS FROM SINGLE ANTIBODY PRODUCING CELLS BY MULTIPLEXED CPR IN COMBINATION WITH TaqMan PROBES - Herein is reported a method for a multiplex one tube real-time reverse-transcriptase gene-specific polymerase chain reaction for the amplification and quantification of cognate IgG heavy and light chains encoding nucleic acids (human IgG isotype) from a single cell. | 01-22-2015 |